Pfizer to Buy Medivation for $14 Billion - Wall Street Journal
| Wall Street Journal | Pfizer to Buy Medivation for $14 Billion Wall Street Journal Pfizer Inc. said Monday that it had agreed to buy biotech Medivation Inc. MDVN -0.04 % for about $14 billion, in a move that adds one of the crown jewels of the multibillion-dollar market for cancer drugs to Pfizer's portfolio. News of the impending ... UPDATED: Pfizer buys Medivation for $81.50 a share Pfizer (PFE) to Acquire Medivation (MDVN) in $14B Deal Pfizer to shell out $14B for most-wanted M&A target Medivation |